Valion Bio, Inc. Common Stock (VBIO) Expected to Post Quarterly Earnings on Monday

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) is anticipated to release its Q2 2026 resultson Monday, August 17th. Analysts expect Valion Bio, Inc. Common Stock to announce earnings of ($408.00) per share and revenue of $0.46 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 20, 2026 at 4:30 PM ET.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($2.23) earnings per share (EPS) for the quarter.

Valion Bio, Inc. Common Stock Price Performance

VBIO opened at $0.29 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.02 and a current ratio of 3.31. The company has a market capitalization of $1.18 million, a PE ratio of -0.04 and a beta of 1.85. The stock’s fifty day moving average is $0.49 and its 200-day moving average is $0.81. Valion Bio, Inc. Common Stock has a one year low of $0.25 and a one year high of $5.60.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Valion Bio, Inc. Common Stock currently has an average rating of “Sell”.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.